Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Recruiting Observational

Children to Adults Mental and Psychosomatic Health Study (CAMPS)

NCT05621278 · tracked via the Priya Life Science China tracker
Phase
Observational
Started
2022-09-11
Last updated
2024-04-24

Condition(s) studied

Mental Health WellnessCognitive FunctionPhysical Symptoms

Study summary

This study titled the Children to Adults Mental and Psychosomatic Health Study (CAMPS), aims to explore the interplay between mental health, psychosomatic factors, and adverse childhood experiences (ACE) across a broad age range, from school-age children to adults in China. The study will involve participants from various educational settings, including teachers, students, and parents, who will be recruited through schools. The assessment methodology will combine validated psychometric scales and behavioral experiments to comprehensively evaluate mental and physical health aspects and the impact of ACEs. This integrative approach is designed to illuminate the complex relationships between psychological well-being, somatic symptoms, and early life stressors across different life stages.

Eligibility

Sex
ALL
Min age
9 Years
Max age
65 Years
Healthy volunteers
Accepted
Inclusion Criteria: 1. Students from 5 grade to 12 grade, their parents and teachers 2. able to read, answer questionnaires and complete experiments. Exclusion Criteria: a. Students who suspend schooling.

Primary outcome measure(s)

  • Irritability — 1 month
    A 17-item irritability measurement scale, the Peking irritability scale, measures impulsive emotions, thoughts, and behaviors on a 5-point Likert scale (score from 1 to 5, and total score varies from 17 to 85). A higher score represents higher irritability.
  • Alexithymia — 1 month
    A 36-item Peking alexithymia scale measures thoughts and behaviors that prevent people from feeling or recognizing negative emotions on a 5-point Likert scale (1 to 5, and total scores vary from 36 to 180). A higher score represents more severe alexithymia.
  • Depression for adults — 2 weeks
    The 9-item patient health questionnaire (PHQ-9) for adults (score from 0 to 3, and total score varies from 0 to 27). A higher score represents worse depression symptoms.
  • Depression — 2 weeks
    Children's depression inventory (CDI) for adolescents and children (score from 0 to 2, and total score vary from 0 to 54). A higher score represents worse depression symptoms.
  • Generalized anxiety disorder — 2 weeks
    The Generalized Anxiety Disorder-7 scale (GAD-7) for adults, adolescents, and children (scored from 0 to 3, and total score from 0 to 21). A higher score represents worse anxiety symptoms.
  • Anxiety and depression for adolescents and children — 2 weeks
    The Revised Child Anxiety and Depression Scale (RCADS) for adolescents and children (scored from 0 to 3, and total score from 0 to 75). A higher score represents worse anxiety and depression symptoms.
  • PTSD for adults — 1 month
    The PTSD Symptoms Scale-Interview for DSM-5 (PSSI-5) for adults (score from 0 to 4, and total scores vary from 0 to 80). A higher score represents worse PTSD symptoms.
  • PTSD for adolescents and children — 1 month
    The Child PTSD Symptom Scale for DSM-5 (CPSS-5) for adolescents and children (scores from 0 to 4, and total scores vary from 0 to 80). A higher score represents worse PTSD symptoms.
  • NSSI — 1 year
    The non-suicidal self-injury assessment tool (NSSI-AT-Severity) for adolescents and children (total scores vary from 5 to 16). A higher score represents a worse self-injury situation.
  • Suicide — 1 year
    The suicidal behaviors questionnaire-revised (SBQ-R) for adolescents and children (total scores vary from 3 to 18). A higher score represents a higher suicide risk.
  • Emotion recognition — Half year
    The Morph task for adolescents to examine the emotion recognition capability.
  • Excutive function — Half year
    The Go/Nogo task for adolescents is to examine inhibition function.
  • Adverse Childhood Experiences (ACE) — each year
    A questionnaire measuring adverse childhood experiences with 26 items.

Trial sites (1)

FacilityCityRegionStatus
Peking University Beijing Beijing Municipality Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT05621278 on ClinicalTrials.gov ↗ ← All trials in China